Chemopreventive agents and inhibitors of cancer hallmarks: May citrus offer new perspectives?

Nutrients

Volumn 8, Issue 11, 2016, Pages

  Cirmi, Santa ^a   Ferlazzo, Nadia ^a   Lombardo, Giovanni E ^b   Maugeri, Alessandro ^a   Calapai, Gioacchino ^a   Gangemi, Sebastiano ^c,d   Navarra, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d CNR   (Italy)

Author keywords

Cancer; Citrus; Complementary and alternative medicines; Flavonoids; Functional foods; Natural product; Nutraceuticals

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ANTINEOPLASTIC AGENT; APIGENIN; ASCORBIC ACID; AURANTIIN; AZOXYMETHANE; BENZO[A]PYRENE; BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DIDYMIN; DIETHYLNITROSAMINE; DIMETHYLBENZ[A]ANTHRACENE; DIOSMIN; FLAVONOID; INTERLEUKIN 6; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE; MYRICETIN; NARINGENIN; NOBILETIN; NUTRACEUTICAL; QUERCETIN; REACTIVE OXYGEN METABOLITE; RUTOSIDE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TANGERETIN; TAXIFOLIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CITRUS FRUIT; CLINICAL TRIAL (TOPIC); DIET; DIETARY SUPPLEMENT; DNA DAMAGE; DNA REPAIR; GENOTOXICITY; HUMAN; IC50; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; REVIEW; SYSTEMATIC REVIEW (TOPIC); CHEMISTRY; CITRUS; FRUIT; NEOPLASMS; VEGETABLE;

ANTICARCINOGENIC AGENTS; CITRUS; DIETARY SUPPLEMENTS; FLAVONOIDS; FRUIT; HUMANS; NEOPLASMS; VEGETABLES;

EID: 84995437649     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8110698     Document Type: Review

References (285)

1. International Agency for Research on Cancer (IARC). World Cancer Report 2014. Available online: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014 (accessed on 5 August 2016).
2. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461–477. [CrossRef] [PubMed]
3. Gerber, M. The comprehensive approach to diet: A critical review. J. Nutr. 2001, 131, 3051S–3055S. [PubMed]
4. Manson, M.M. Cancer prevention—The potential for diet to modulate molecular signalling. Trends Mol. Med. 2003, 9, 11–18. [CrossRef]
5. Middleton, E.; Kandaswami, C.; Theoharides, T.C. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673–751. [PubMed]
6. Tomasetti, C.; Vogelstein, B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015, 347, 78–81. [CrossRef] [PubMed]
7. Amin, A.R.M.R.; Kucuk, O.; Khuri, F.R.; Shin, D.M. Perspectives for cancer prevention with natural compounds. J. Clin. Oncol. 2009, 27, 2712–2725. [CrossRef] [PubMed]
8. Gullett, N.P.; Ruhul Amin, A.R.; Bayraktar, S.; Pezzuto, J.M.; Shin, D.M.; Khuri, F.R.; Aggarwal, B.B.; Surh, Y.J.; Kucuk, O. Cancer prevention with natural compounds. Semin. Oncol. 2010, 37, 258–281. [CrossRef] [PubMed]
9. Milner, J.A.; McDonald, S.S.; Anderson, D.E.; Greenwald, P. Molecular targets for nutrients involved with cancer prevention. Nutr. Cancer Int. J. 2001, 41, 1–16.
10. Surh, Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768–780.
11. Micali, S.; Isgro, G.; Bianchi, G.; Miceli, N.; Calapai, G.; Navarra, M. Cranberry and recurrent cystitis: More than marketing? Crit. Rev. Food Sci. Nutr. 2014, 54, 1063–1075.
12. Paterniti, I.; Cordaro, M.; Campolo, M.; Siracusa, R.; Cornelius, C.; Navarra, M.; Cuzzocrea, S.; Esposito, E. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental alzheimer’s disease models: The control of neuroinflammation. CNS Neurol. Disord. Drug Targets 2014, 13, 1530–1541.
13. Nogata, Y.; Sakamoto, K.; Shiratsuchi, H.; Ishii, T.; Yano, M.; Ohta, H. Flavonoid composition of fruit tissues of citrus species. Biosci. Biotechnol. Biochem. 2006, 70, 178–192.
14. Benavente-Garcia, O.; Castillo, J. Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food Chem. 2008, 56, 6185–6205.
15. Pouget, C.; Lauthier, F.; Simon, A.; Fagnere, C.; Basly, J.P.; Delage, C.; Chulia, A.J. Flavonoids: Structural requirements for antiproliferative activity on breast cancer cells. Bioorg. Med. Chem. Lett. 2001, 11, 3095–3097.
16. Yanez, J.; Vicente, V.; Alcaraz, M.; Castillo, J.; Benavente-Garcia, O.; Canteras, M.; Teruel, J.A.L. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: Relationship between structure and activity. Nutr. Cancer Int. J. 2004, 49, 191–199.
17. Rodriguez, J.; Yanez, J.; Vicente, V.; Alcaraz, M.; Benavente-Garcia, O.; Castillo, J.; Lorente, J.; Lozano, J.A. Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines: Relationship between structure and activity. Melanoma Res. 2002, 12, 99–107.
18. Martinez, C.; Yanez, J.; Vicente, V.; Alcaraz, M.; Benavente-Garcia, O.; Castillo, J.; Lorente, J.; Lozano, J.A. Effects of several polyhydroxylated flavonoids on the growth of B16F10 melanoma and melan-a melanocyte cell lines: Influence of the sequential oxidation state of the flavonoid skeleton. Melanoma Res. 2003, 13, 3–9.
19. Hursting, S.D.; Cantwell, M.M.; Sansbury, L.B.; Forman, M.R. Nutrition and cancer prevention: Targets, strategies, and the importance of early life interventions. In Proceedings of the 57th Nestlé Nutrition Workshop, Pediatric Program, Half Moon Bay, San Francisco, CA, USA, 24–28 May 2005; Lucas, A., Sampson, H.A., Eds.; Nestec Ltd.: Basel, Switzerland, 2006; pp. 153–202.
20. Mandl, J.; Szarka, A.; Banhegyi, G. Vitamin C: Update on physiology and pharmacology. Br. J. Pharmacol. 2009, 157, 1097–1110.
21. Williams, R.J.; Spencer, J.P.; Rice-Evans, C. Flavonoids: Antioxidants or signalling molecules? Free Radic. Biol. Med. 2004, 36, 838–849.
22. Manthey, J.A.; Grohmann, K.; Guthrie, N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr. Med. Chem. 2001, 8, 135–153.
23. Nyberg, F.; Hou, S.M.; Pershagen, G.; Lambert, B. Dietary fruit and vegetables protect against somatic mutation in vivo, but low or high intake of carotenoids does not. Carcinogenesis 2003, 24, 689–696.
24. Calomme, M.; Pieters, L.; Vlietinck, A.; Vanden Berghe, D. Inhibition of bacterial mutagenesis by citrus flavonoids. Planta Med. 1996, 62, 222–226.
25. Kootstra, A. Protection from UV-B-induced DNA damage by flavonoids. Plant Mol. Biol. 1994, 26, 771–774.
26. Barcelos, G.R.; Angeli, J.P.; Serpeloni, J.M.; Grotto, D.; Rocha, B.A.; Bastos, J.K.; Knasmuller, S.; Junior, F.B. Quercetin protects human-derived liver cells against mercury-induced DNA-damage and alterations of the redox status. Mutat. Res. 2011, 726, 109–115.
27. Gao, K.; Henning, S.M.; Niu, Y.T.; Youssefian, A.A.; Seeram, N.P.; Xu, A.L.; Heber, D. The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J. Nutr. Biochem. 2006, 17, 89–95.
28. Arul, D.; Subramanian, P. Inhibitory effect of naringenin (Citrus flavonone) on N-nitrosodiethylamine induced hepatocarcinogenesis in rats. Biochem. Biophys. Res. Commun. 2013, 434, 203–209.
29. Subramanian, P.; Arul, D. Attenuation of ndea-induced hepatocarcinogenesis by naringenin in rats. Cell Biochem. Funct. 2013, 31, 511–517.
30. Alvarez-Gonzalez, I.; Madrigal-Bujaidar, E.; Dorado, V.; Espinosa-Aguirre, J.J. Inhibitory effect of naringin on the micronuclei induced by ifosfamide in mouse, and evaluation of its modulatory effect on the CYP3A subfamily. Mutat. Res. 2001, 480, 171–178.
31. Carino-Cortes, R.; Alvarez-Gonzalez, I.; Martino-Roaro, L.; Madrigal-Bujaidar, E. Effect of naringin on the DNA damage induced by daunorubicin in mouse hepatocytes and cardiocytes. Biol. Pharm. Bull. 2010, 33, 697–701.
32. Sequetto, P.L.; Oliveira, T.T.; Maldonado, I.R.; Augusto, L.E.; Mello, V.J.; Pizziolo, V.R.; Almeida, M.R.; Silva, M.E.; Novaes, R.D. Naringin accelerates the regression of pre-neoplastic lesions and the colorectal structural reorganization in a murine model of chemical carcinogenesis. Food Chem. Toxicol. 2014, 64, 200–209.
33. Ahmadi, A.; Hosseinimehr, S.J.; Naghshvar, F.; Hajir, E.; Ghahremani, M. Chemoprotective effects of hesperidin against genotoxicity induced by cyclophosphamide in mice bone marrow cells. Arch. Pharm. Res. 2008, 31, 794–797.
34. Choi, J.S.; Park, K.Y.; Moon, S.H.; Rhee, S.H.; Young, H.S. Antimutagenic effect of plant flavonoids in the salmonella assay system. Arch. Pharm. Res. 1994, 17, 71–75.
35. Kao, Y.C.; Zhou, C.; Sherman, M.; Laughton, C.A.; Chen, S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ. Health Perspect. 1998, 106, 85–92.
36. Harris, R.M.; Wood, D.M.; Bottomley, L.; Blagg, S.; Owen, K.; Hughes, P.J.; Waring, R.H.; Kirk, C.J. Phytoestrogens are potent inhibitors of estrogen sulfation: Implications for breast cancer risk and treatment. J. Clin. Endocrinol. Metab. 2004, 89, 1779–1787.
37. Bear, W.L.; Teel, R.W. Effects of Citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res. 2000, 20, 3609–3614.
38. Van Dross, R.; Xue, Y.; Knudson, A.; Pelling, J.C. The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines. J. Nutr. 2003, 133, 3800S–3804S.
39. Khan, T.H.; Jahangir, T.; Prasad, L.; Sultana, S. Inhibitory effect of apigenin on benzo(a)pyrene-mediated genotoxicity in swiss albino mice. J. Pharm. Pharmacol. 2006, 58, 1655–1660.
40. Myhrstad, M.C.; Carlsen, H.; Nordstrom, O.; Blomhoff, R.; Moskaug, J.O. Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic. Biol. Med. 2002, 32, 386–393.
41. Wei, H.; Tye, L.; Bresnick, E.; Birt, D.F. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 1990, 50, 499–502.
42. Birt, D.F.; Mitchell, D.; Gold, B.; Pour, P.; Pinch, H.C. Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res. 1997, 17, 85–91.
43. Leonardi, T.; Vanamala, J.; Taddeo, S.S.; Davidson, L.A.; Murphy, M.E.; Patil, B.S.; Wang, N.; Carroll, R.J.; Chapkin, R.S.; Lupton, J.R.; et al. Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp. Biol. Med. (Maywood) 2010, 235, 710–717.
44. Nandakumar, N.; Balasubramanian, M.P. Hesperidin protects renal and hepatic tissues against free radical-mediated oxidative stress during DMBA-induced experimental breast cancer. J. Environ. Pathol. Toxicol. Oncol. 2011, 30, 283–300.
45. Aranganathan, S.; Selvam, J.P.; Sangeetha, N.; Nalini, N. Modulatory efficacy of hesperetin (Citrus flavanone) on xenobiotic-metabolizing enzymes during 1,2-dimethylhydrazine-induced colon carcinogenesis. Chem. Biol. Interact. 2009, 180, 254–261.
46. Lakshmi, A.; Subramanian, S. Chemotherapeutic effect of tangeretin, a polymethoxylated flavone studied in 7,12-dimethylbenz(a)anthracene induced mammary carcinoma in experimental rats. Biochimie 2014, 99, 96–109.
47. Murakami, A.; Nakamura, Y.; Torikai, K.; Tanaka, T.; Koshiba, T.; Koshimizu, K.; Kuwahara, S.; Takahashi, Y.; Ogawa, K.; Yano, M.; et al. Inhibitory effect of Citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res. 2000, 60, 5059–5066.
48. Kandaswami, C.; Perkins, E.; Soloniuk, D.S.; Drzewiecki, G.; Middleton, E., Jr. Antiproliferative effects of citrus flavonoids on a human squamous cell carcinoma in vitro. Cancer Lett. 1991, 56, 147–152.
49. Sugiyama, S.; Umehara, K.; Kuroyanagi, M.; Ueno, A.; Taki, T. Studies on the differentiation inducers of myeloid leukemic cells from Citrus species. Chem. Pharm. Bull. (Tokyo) 1993, 41, 714–719.
50. Hirano, T.; Abe, K.; Gotoh, M.; Oka, K. Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br. J. Cancer 1995, 72, 1380–1388.
51. Morley, K.L.; Ferguson, P.J.; Koropatnick, J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett. 2007, 251, 168–178.
52. Pan, M.H.; Chen, W.J.; Lin-Shiau, S.Y.; Ho, C.T.; Lin, J.K. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002, 23, 1677–1684.
53. Yoshimizu, N.; Otani, Y.; Saikawa, Y.; Kubota, T.; Yoshida, M.; Furukawa, T.; Kumai, K.; Kameyama, K.; Fujii, M.; Yano, M.; et al. Anti-tumour effects of nobiletin, a Citrus flavonoid, on gastric cancer include: Antiproliferative effects, induction of apoptosis and cell cycle deregulation. Aliment. Pharmacol. Ther. 2004, 20 (Suppl. 1), 95–101.
54. Fan, K.; Kurihara, N.; Abe, S.; Ho, C.T.; Ghai, G.; Yang, K. Chemopreventive effects of orange peel extract (OPE) I: Ope inhibits intestinal tumor growth in Apc(min/+) mice. J. Med. Food 2007, 10, 11–17.
55. Abe, S.; Fan, K.; Ho, C.T.; Ghai, G.; Yang, K. Chemopreventive effects of orange peel extract (OPE) II: OPE inhibits atypical hyperplastic lesions in rodent mammary gland. J. Med. Food 2007, 10, 18–24.
56. Van Slambrouck, S.; Parmar, V.S.; Sharma, S.K.; de Bondt, B.; Fore, F.; Coopman, P.; Vanhoecke, B.W.; Boterberg, T.; Depypere, H.T.; Leclercq, G.; et al. Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation. FEBS Lett. 2005, 579, 1665–1669.
57. Akao, Y.; Itoh, T.; Ohguchi, K.; Iinuma, M.; Nozawa, Y. Interactive effects of polymethoxy flavones from Citrus on cell growth inhibition in human neuroblastoma SH-SY5Y cells. Bioorg. Med. Chem. 2008, 16, 2803–2810.
58. Rooprai, H.K.; Kandanearatchi, A.; Maidment, S.L.; Christidou, M.; Trillo-Pazos, G.; Dexter, D.T.; Rucklidge, G.J.; Widmer, W.; Pilkington, G.J. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol. Appl. Neurobiol. 2001, 27, 29–39.
59. Arafa el, S.A.; Zhu, Q.; Barakat, B.M.; Wani, G.; Zhao, Q.; El-Mahdy, M.A.; Wani, A.A. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009, 69, 8910–8917.
60. Dong, Y.; Cao, A.L.; Shi, J.R.; Yin, P.H.; Wang, L.; Ji, G.; Xie, J.Q.; Wu, D.Z. Tangeretin, a citrus polymethoxyflavonoid, induces apoptosis of human gastric cancer AGS cells through extrinsic and intrinsic signaling pathways. Oncol. Rep. 2014, 31, 1788–1794.
61. Tang, M.; Ogawa, K.; Asamoto, M.; Hokaiwado, N.; Seeni, A.; Suzuki, S.; Takahashi, S.; Tanaka, T.; Ichikawa, K.; Shirai, T. Protective effects of Citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci. 2007, 98, 471–477.
62. Tang, M.X.; Ogawa, K.; Asamoto, M.; Chewonarin, T.; Suzuki, S.; Tanaka, T.; Shirai, T. Effects of nobiletin on PhIP-induced prostate and colon carcinogenesis in F344 rats. Nutr. Cancer 2011, 63, 227–233.
63. Suzuki, R.; Kohno, H.; Murakami, A.; Koshimizu, K.; Ohigashi, H.; Yano, M.; Tokuda, H.; Nishino, H.; Tanaka, T. Citrus nobiletin inhibits azoxymethane-induced large bowel carcinogenesis in rats. Biofactors 2004, 22, 111–114.
64. Miyamoto, S.; Yasui, Y.; Ohigashi, H.; Tanaka, T.; Murakami, A. Dietary flavonoids suppress azoxymethane-induced colonic preneoplastic lesions in male C57BL/KSJ-DB/DB mice. Chem. Biol. Interact. 2010, 183, 276–283.
65. Miyamoto, S.; Yasui, Y.; Tanaka, T.; Ohigashi, H.; Murakami, A. Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. Carcinogenesis 2008, 29, 1057–1063.
66. Luo, G.; Guan, X.; Zhou, L. Apoptotic effect of Citrus fruit extract nobiletin on lung cancer cell line a549 in vitro and in vivo. Cancer Biol. Ther. 2008, 7, 966–973.
67. Ohnishi, H.; Asamoto, M.; Tujimura, K.; Hokaiwado, N.; Takahashi, S.; Ogawa, K.; Kuribayashi, M.; Ogiso, T.; Okuyama, H.; Shirai, T. Inhibition of cell proliferation by nobiletin, a dietary phytochemical, associated with apoptosis and characteristic gene expression, but lack of effect on early rat hepatocarcinogenesis in vivo. Cancer Sci. 2004, 95, 936–942.
68. Aoki, K.; Yokosuka, A.; Mimaki, Y.; Fukunaga, K.; Yamakuni, T. Nobiletin induces inhibitions of RAS activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells. Biol. Pharm. Bull. 2013, 36, 540–547.
69. Lien, L.M.; Wang, M.J.; Chen, R.J.; Chiu, H.C.; Wu, J.L.; Shen, M.Y.; Chou, D.S.; Sheu, J.R.; Lin, K.H.; Lu, W.J. Nobiletin, a polymethoxylated flavone, inhibits glioma cell growth and migration via arresting cell cycle and suppressing MAPK and Akt pathways. Phytother. Res. 2016, 30, 214–221.
70. Moon, J.Y.; Cho, M.; Ahn, K.S.; Cho, S.K. Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells. Nutr. Cancer Int. J. 2013, 65, 286–295.
71. Hsiao, P.C.; Lee, W.J.; Yang, S.F.; Tan, P.; Chen, H.Y.; Lee, L.M.; Chang, J.L.; Lai, G.M.; Chow, J.M.; Chien, M.H. Nobiletin suppresses the proliferation and induces apoptosis involving MAPKs and caspase-8/-9/-3 signals in human acute myeloid leukemia cells. Tumor Biol. 2014, 35, 11903–11911.
72. Wu, X.; Song, M.Y.; Wang, M.Q.; Zheng, J.K.; Gao, Z.L.; Xu, F.; Zhang, G.D.; Xiao, H. Chemopreventive effects of nobiletin and its colonic metabolites on colon carcinogenesis. Mol. Nutr. Food Res. 2015, 59, 2383–2394.
73. Choi, E.J.; Kim, G.H. Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J. Clin. Biochem. Nutr. 2009, 44, 260–265.
74. Seo, H.S.; Choi, H.S.; Kim, S.R.; Choi, Y.K.; Woo, S.M.; Shin, I.; Woo, J.K.; Park, S.Y.; Shin, Y.C.; Ko, S.K. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells. Mol. Cell. Biochem. 2012, 366, 319–334.
75. Way, T.D.; Kao, M.C.; Lin, J.K. Apigenin induces apoptosis through proteasomal degradation of HER2/NEU in HER2/NEU-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 2004, 279, 4479–4489.
76. Agrawal, A.; Yang, J.; Murphy, R.F.; Agrawal, D.K. Regulation of the p14ARF-MDM2-p53 pathway: An overview in breast cancer. Exp. Mol. Pathol. 2006, 81, 115–122.
77. Takagaki, N.; Sowa, Y.; Oki, T.; Nakanishi, R.; Yogosawa, S.; Sakai, T. Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int. J. Oncol. 2005, 26, 185–189.
78. Lepley, D.M.; Pelling, J.C. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol. Carcinog. 1997, 19, 74–82.
79. Plaumann, B.; Fritsche, M.; Rimpler, H.; Brandner, G.; Hess, R.D. Flavonoids activate wild-type p53. Oncogene 1996, 13, 1605–1614.
80. Yin, F.; Giuliano, A.E.; Law, R.E.; Van Herle, A.J. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP Kinase activation in breast carcinoma cells. Anticancer Res. 2001, 21, 413–420.
81. King, J.C.; Lu, Q.Y.; Li, G.; Moro, A.; Takahashi, H.; Chen, M.; Go, V.L.; Reber, H.A.; Eibl, G.; Hines, O.J. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim. Biophys. Acta 2012, 1823, 593–604.
82. Ujiki, M.B.; Ding, X.Z.; Salabat, M.R.; Bentrem, D.J.; Golkar, L.; Milam, B.; Talamonti, M.S.; Bell, R.H., Jr.; Iwamura, T.; Adrian, T.E. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5, 76. [CrossRef]
83. Johnson, J.L.; de Mejia, E.G. Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3 beta/NFκB signaling cascade. Mol. Nutr. Food Res. 2013, 57, 2112–2127.
84. Gupta, S.; Afaq, F.; Mukhtar, H. Involvement of nuclear factor-kappa B, BAX and BCL-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002, 21, 3727–3738.
85. Shukla, S.; Gupta, S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol. Carcinog. 2004, 39, 114–126.
86. Wang, W.; Heideman, L.; Chung, C.S.; Pelling, J.C.; Koehler, K.J.; Birt, D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol. Carcinog. 2000, 28, 102–110.
87. Zhong, Y.; Krisanapun, C.; Lee, S.H.; Nualsanit, T.; Sams, C.; Peungvicha, P.; Baek, S.J. Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53. Eur. J. Cancer 2010, 46, 3365–3374.
88. Shukla, S.; Gupta, S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol. Cancer Ther. 2006, 5, 843–852.
89. Das, A.; Banik, N.L.; Ray, S.K. Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. Int. J. Cancer 2006, 119, 2575–2585.
90. Torkin, R.; Lavoie, J.F.; Kaplan, D.R.; Yeger, H. Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol. Cancer Ther. 2005, 4, 1–11.
91. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
92. Kuntz, S.; Wenzel, U.; Daniel, H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur. J. Nutr. 1999, 38, 133–142.
93. Dung, T.D.; Day, C.H.; Binh, T.V.; Lin, C.H.; Hsu, H.H.; Su, C.C.; Lin, Y.M.; Tsai, F.J.; Kuo, W.W.; Chen, L.M.; et al. PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K-Akt-MDM2 signaling suppression. Food Chem. Toxicol. 2012, 50, 1802–1810.
94. Lewinska, A.; Siwak, J.; Rzeszutek, I.; Wnuk, M. Diosmin induces genotoxicity and apoptosis in DU145 prostate cancer cell line. Toxicol. Vitr. 2015, 29, 417–425.
95. Tanaka, T.; Makita, H.; Kawabata, K.; Mori, H.; Kakumoto, M.; Satoh, K.; Hara, A.; Sumida, T.; Fukutani, K.; Tanaka, T.; et al. Modulation of N-methyl-N-amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination. Carcinogenesis 1997, 18, 761–769.
96. Tanaka, T.; Makita, H.; Ohnishi, M.; Mori, H.; Satoh, K.; Hara, A.; Sumida, T.; Fukutani, K.; Tanaka, T.; Ogawa, H. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res. 1997, 57, 246–252.
97. Yang, M.; Tanaka, T.; Hirose, Y.; Deguchi, T.; Mori, H.; Kawada, Y. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int. J. Cancer 1997, 73, 719–724.
98. Tanaka, T.; Makita, H.; Kawabata, K.; Mori, H.; Kakumoto, M.; Satoh, K.; Hara, A.; Sumida, T.; Tanaka, T.; Ogawa, H. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997, 18, 957–965.
99. Rubio, S.; Quintana, J.; Lopez, M.; Eiroa, J.L.; Triana, J.; Estevez, F. Phenylbenzopyrones structure-activity studies identify betuletol derivatives as potential antitumoral agents. Eur. J. Pharmacol. 2006, 548, 9–20.
100. Duraj, J.; Zazrivcova, K.; Bodo, J.; Sulikova, M.; Sedlak, J. Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 2005, 52, 273–279.
101. Piantelli, M.; Rinelli, A.; Macri, E.; Maggiano, N.; Larocca, L.M.; Scerrati, M.; Roselli, R.; Iacoangeli, M.; Scambia, G.; Capelli, A.; et al. Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas. Cancer 1993, 71, 193–198.
102. Kuo, S.M. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett. 1996, 110, 41–48.
103. Araujo, J.R.; Goncalves, P.; Martel, F. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr. Res. 2011, 31, 77–87.
104. Paliwal, S.; Sundaram, J.; Mitragotri, S. Induction of cancer-specific cytotoxicity towards human prostate and skin cells using quercetin and ultrasound. Br. J. Cancer 2005, 92, 499–502.
105. Huang, H.C.; Lin, C.L.; Lin, J.K. 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of SKP2 protein. J. Agric. Food Chem. 2011, 59, 6765–6775.
106. Li, J.; Zhu, F.; Lubet, R.A.; De Luca, A.; Grubbs, C.; Ericson, M.E.; D’Alessio, A.; Normanno, N.; Dong, Z.; Bode, A.M. Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. Mol. Carcinog. 2011, 52, 134–143.
107. Staedler, D.; Idrizi, E.; Kenzaoui, B.H.; Juillerat-Jeanneret, L. Drug combinations with quercetin: Doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother. Pharmacol. 2011, 68, 1161–1172.
108. Scambia, G.; Ranelletti, F.O.; Panici, P.B.; De Vincenzo, R.; Bonanno, G.; Ferrandina, G.; Piantelli, M.; Bussa, S.; Rumi, C.; Cianfriglia, M.; et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 1994, 34, 459–464.
109. Critchfield, J.W.; Welsh, C.J.; Phang, J.M.; Yeh, G.C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of p-glycoprotein as a putative mechanism. Biochem. Pharmacol. 1994, 48, 1437–1445.
110. Kanno, S.; Tomizawa, A.; Hiura, T.; Osanai, Y.; Shouji, A.; Ujibe, M.; Ohtake, T.; Kimura, K.; Ishikawa, M. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharm. Bull. 2005, 28, 527–530.
111. Kanno, S.; Tomizawa, A.; Ohtake, T.; Koiwai, K.; Ujibe, M.; Ishikawa, M. Naringenin-induced apoptosis via activation of NF-κB and necrosis involving the loss of ATP in human promyeloleukemia HL-60 cells. Toxicol. Lett. 2006, 166, 131–139.
112. Frydoonfar, H.R.; McGrath, D.R.; Spigelman, A.D. The variable effect on proliferation of a colon cancer cell line by the Citrus fruit flavonoid naringenin. Colorectal Dis. 2003, 5, 149–152.
113. Harmon, A.W.; Patel, Y.M. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: A mechanism for impaired cellular proliferation. Breast Cancer Res. Treat. 2004, 85, 103–110.
114. Park, J.H.; Jin, C.Y.; Lee, B.K.; Kim, G.Y.; Choi, Y.H.; Jeong, Y.K. Naringenin induces apoptosis through downregulation of AKT and caspase-3 activation in human leukemia THP-1 cells. Food Chem. Toxicol. 2008, 46, 3684–3690.
115. Shi, D.; Xu, Y.; Du, X.; Chen, X.; Zhang, X.; Lou, J.; Li, M.; Zhuo, J. Co-treatment of THP-1 cells with naringenin and curcumin induces cell cycle arrest and apoptosis via numerous pathways. Mol. Med. Rep. 2015, 12, 8223–8228.
116. Ahamad, M.S.; Siddiqui, S.; Jafri, A.; Ahmad, S.; Afzal, M.; Arshad, M. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest. PLoS ONE 2014, 9, e110003.
117. Naoghare, P.K.; Ki, H.A.; Paek, S.M.; Tak, Y.K.; Suh, Y.G.; Kim, S.G.; Leeb, K.H.; Song, J.M. Simultaneous quantitative monitoring of drug-induced caspase cascade pathways in carcinoma cells. Integr. Biol. 2010, 2, 46–57.
118. Jin, C.Y.; Park, C.; Hwang, H.J.; Kim, G.Y.; Choi, B.T.; Kim, W.J.; Choi, Y.H. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol. Nutr. Food Res. 2011, 55, 300–309.
119. Zhang, S.Z.; Yang, X.N.; Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 2004, 65, 1208–1216.
120. Zhang, S.Z.; Yang, X.N.; Coburn, R.A.; Morris, M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol. 2005, 70, 627–639.
121. Romiti, N.; Tramonti, G.; Donati, A.; Chieli, E. Effects of grapefruit juice on the multidrug transporter p-glycoprotein in the human proximal tubular cell line HK-2. Life Sci. 2004, 76, 293–302.
122. Tsai, T.H.; Lee, C.H.; Yeh, P.H. Effect of p-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis. Br. J. Pharmacol. 2001, 134, 1245–1252.
123. De Castro, W.V.; Mertens-Talcott, S.; Derendorf, H.; Butterweck, V. Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J. Agric. Food Chem. 2008, 56, 4840–4845.
124. Zhang, F.Y.; Du, G.J.; Zhang, L.; Zhang, C.L.; Lu, W.L.; Liang, W. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not p-glycoprotein. Pharm. Res. 2009, 26, 914–925.
125. Park, H.S.; Oh, J.H.; Lee, J.H.; Lee, Y.J. Minor effects of the citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats. Pharmazie 2011, 66, 424–429.
126. Ekambaram, G.; Rajendran, P.; Magesh, V.; Sakthisekaran, D. Naringenin reduces tumor size and weight lost in N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Nutr. Res. 2008, 28, 106–112.
127. Ganapathy, E.; Peramaiyan, R.; Rajasekaran, D.; Venkataraman, M.; Dhanapal, S. Modulatory effect of naringenin on N-methyl-N'-nitro-N-nitrosoguanidine-and saturated sodium chloride-induced gastric carcinogenesis in male wistar rats. Clin. Exp. Pharmacol. Physiol. 2008, 35, 1190–1196.
128. Sabarinathan, D.; Mahalakshmi, P.; Vanisree, A.J. Naringenin promote apoptosis in cerebrally implanted C6 glioma cells. Mol. Cell. Biochem. 2010, 345, 215–222.
129. Miller, E.G.; Peacock, J.J.; Bourland, T.C.; Taylor, S.E.; Wright, J.A.; Patil, B.S.; Miller, E.G. Inhibition of oral carcinogenesis by Citrus flavonoids. Nutr. Cancer Int. J. 2008, 60, 69–74.
130. Ramesh, E.; Alshatwi, A.A. Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem. Toxicol. 2013, 51, 97–105.
131. Zeng, L.; Zhen, Y.; Chen, Y.; Zou, L.; Zhang, Y.; Hu, F.; Feng, J.; Shen, J.; Wei, B. Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NFκB/COX2caspase-1 pathway in HeLa cervical cancer cells. Int. J. Oncol. 2014, 45, 1929–1936.
132. Yoshinaga, A.; Kajiya, N.; Oishi, K.; Kamada, Y.; Ikeda, A.; Chigwechokha, P.K.; Kibe, T.; Kishida, M.; Kishida, S.; Komatsu, M.; et al. Neu3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation. Eur. J. Pharmacol. 2016, 782, 21–29.
133. Li, H.; Yang, B.; Huang, J.; Xiang, T.; Yin, X.; Wan, J.; Luo, F.; Zhang, L.; Li, H.; Ren, G. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting beta-catenin signaling pathway. Toxicol. Lett. 2013, 220, 219–228.
134. Kim, D.I.; Lee, S.J.; Lee, S.B.; Park, K.; Kim, W.J.; Moon, S.K. Requirement for RAS/RAF/ERK pathway in naringin-induced G(1)-cell-cycle arrest via p21WAF1 expression. Carcinogenesis 2008, 29, 1701–1709.
135. Xie, C.M.; Chan, W.Y.; Yu, S.; Zhao, J.; Cheng, C.H. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic. Biol. Med. 2011, 51, 1365–1375.
136. Chen, Y.J.; Chi, C.W.; Su, W.C.; Huang, H.L. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget 2014, 5, 4845–4854.
137. Raha, S.; Yumnam, S.; Hong, G.E.; Lee, H.J.; Saralamma, V.V.; Park, H.S.; Heo, J.D.; Lee, S.J.; Kim, E.H.; Kim, J.A.; et al. Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/AKT/MTOR cascade via activation of MAPK pathways in AGS cancer cells. Int. J. Oncol. 2015, 47, 1061–1069.
138. Li, J.; Dong, Y.; Hao, G.; Wang, B.; Wang, J.; Liang, Y.; Liu, Y.; Zhen, E.; Feng, D.; Liang, G. Naringin suppresses the development of glioblastoma by inhibiting FAK activity. J. Drug Target. 2016. [CrossRef]
139. Vanamala, J.; Leonardi, T.; Patil, B.S.; Taddeo, S.S.; Murphy, M.E.; Pike, L.M.; Chapkin, R.S.; Lupton, J.R.; Turner, N.D. Suppression of colon carcinogenesis by bioactive compounds in grapefruit. Carcinogenesis 2006, 27, 1257–1265.
140. Camargo, C.A.; Gomes-Marcondes, M.C.C.; Wutzki, N.C.; Aoyama, H. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor alpha levels in rats with Walker 256 carcinosarcoma. Anticancer Res. 2012, 32, 129–133.
141. Zhang, Y.S.; Li, Y.; Wang, Y.; Sun, S.Y.; Jiang, T.; Li, C.; Cui, S.X.; Qu, X.J. Naringin, a natural dietary compound, prevents intestinal tumorigenesis in Apc(min/+) mouse model. J. Cancer Res. Clin. Oncol. 2016, 142, 913–925.
142. Garg, A.; Garg, S.; Zaneveld, L.J.; Singla, A.K. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother. Res. 2001, 15, 655–669.
143. Chen, Y.C.; Shen, S.C.; Lin, H.Y. Rutinoside at C7 attenuates the apoptosis-inducing activity of flavonoids. Biochem. Pharmacol. 2003, 66, 1139–1150.
144. Choi, E.J. Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: Involvement of CDK4 and p21. Nutr. Cancer Int. J. 2007, 59, 115–119.
145. Sivagami, G.; Vinothkumar, R.; Preethy, C.P.; Riyasdeen, A.; Akbarsha, M.A.; Menon, V.P.; Nalini, N. Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT-29 human colon adenocarcinoma cell line—A comparative study. Food Chem. Toxicol. 2012, 50, 660–671.
146. Zarebczan, B.; Pinchot, S.N.; Kunnimalaiyaan, M.; Chen, H. Hesperetin, a potential therapy for carcinoid cancer. Am. J. Surg. 2011, 201, 329–333.
147. Alshatwi, A.A.; Ramesh, E.; Periasamy, V.S.; Subash-Babu, P. The apoptotic effect of hesperetin on human cervical cancer cells is mediated through cell cycle arrest, death receptor, and mitochondrial pathways. Fundam. Clin. Pharmacol. 2013, 27, 581–592.
148. Zhang, J.; Song, J.; Wu, D.; Wang, J.; Dong, W. Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium. Med. Oncol. 2015, 32, 101. [CrossRef]
149. Aranganathan, S.; Nalini, N. Antiproliferative efficacy of hesperetin (Citrus flavanoid) in 1,2-dimethylhydrazineinduced colon cancer. Phytother. Res. 2013, 27, 999–1005.
150. Nalini, N.; Aranganathan, S.; Kabalimurthy, J. Chemopreventive efficacy of hesperetin (Citrus flavonone) against 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Toxicol. Mech. Methods 2012, 22, 397–408.
151. Patil, J.R.; Murthy, K.N.C.; Jayaprakasha, G.K.; Chetti, M.B.; Patil, B.S. Bioactive compounds from mexican lime (Citrus aurantifolia) juice induce apoptosis in human pancreatic cells. J. Agric. Food Chem. 2009, 57, 10933–10942.
152. Park, H.J.; Kim, M.J.; Ha, E.; Chung, J.H. Apoptotic effect of hesperidin through caspase3 activation in human colon cancer cells, SNU-C4. Phytomedicine 2008, 15, 147–151.
153. Banjerdpongchai, R.; Wudtiwai, B.; Khaw-On, P.; Rachakhom, W.; Duangnil, N.; Kongtawelert, P. Hesperidin from Citrus seed induces human hepatocellular carcinoma HepG2 cell apoptosis via both mitochondrial and death receptor pathways. Tumour Biol. 2016, 37, 227–237.
154. Yumnam, S.; Park, H.S.; Kim, M.K.; Nagappan, A.; Hong, G.E.; Lee, H.J.; Lee, W.S.; Kim, E.H.; Cho, J.H.; Shin, S.C.; et al. Hesperidin induces paraptosis like cell death in hepatoblastoma, hepg2 cells: Involvement of ERK1/2 MAPK. PLoS ONE 2014, 9, e101321.
155. Nazari, M.; Ghorbani, A.; Hekmat-Doost, A.; Jeddi-Tehrani, M.; Zand, H. Inactivation of nuclear factor-κB by Citrus flavanone hesperidin contributes to apoptosis and chemo-sensitizing effect in ramos cells. Eur. J. Pharmacol. 2011, 650, 526–533.
156. Ghorbani, A.; Nazari, M.; Jeddi-Tehrani, M.; Zand, H. The Citrus flavonoid hesperidin induces p53 and inhibits NF-kB activation in order to trigger apoptosis in NALM-6 cells: Involvement of ppar gamma-dependent mechanism. Eur. J. Nutr. 2012, 51, 39–46.
157. Palit, S.; Kar, S.; Sharma, G.; Das, P.K. Hesperetin induces apoptosis in breast carcinoma by triggering accumulation of ROS and activation of ASK1/JNK pathway. J. Cell. Physiol. 2015, 230, 1729–1739.
158. Natarajan, N.; Thamaraiselvan, R.; Lingaiah, H.; Srinivasan, P.; Periyasamy, B.M. Effect of flavonone hesperidin on the apoptosis of human mammary carcinoma cell line MCF-7. Biomed. Prev. Nutr. 2011, 1, 207–215.
159. Wang, Y.X.; Yu, H.; Zhang, J.; Gao, J.; Ge, X.; Lou, G. Hesperidin inhibits HeLa cell proliferation through apoptosis mediated by endoplasmic reticulum stress pathways and cell cycle arrest. BMC Cancer 2015, 15. [CrossRef]
160. El-Readi, M.Z.; Hamdan, D.; Farrag, N.; El-Shazly, A.; Wink, M. Inhibition of p-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur. J. Pharmacol. 2010, 626, 139–145. [PubMed]
161. Cooray, H.C.; Janvilisri, T.; van Veen, H.W.; Hladky, S.B.; Barrand, M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun. 2004, 317, 269–275.
162. Lee, C.J.; Wilson, L.; Jordan, M.A.; Nguyen, V.; Tang, J.; Smiyun, G. Hesperidin suppressed proliferations of both human breast cancer and androgen-dependent prostate cancer cells. Phytother. Res. 2010, 24, S15–S19.
163. Tanaka, T.; Makita, H.; Ohnishi, M.; Hirose, Y.; Wang, A.J.; Mori, H.; Satoh, K.; Hara, A.; Ogawa, H. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin—Comparison with the protective effect of beta-carotene. Cancer Res. 1994, 54, 4653–4659.
164. Berkarda, B.; Koyuncu, H.; Soybir, G.; Baykut, F. Inhibitory effect of hesperidin on tumour initiation and promotion in mouse skin. Res. Exp. Med. 1998, 198, 93–99.
165. Koyuncu, H.; Berkarda, B.; Baykut, F.; Soybir, G.; Alatli, C.; Gul, H.; Altun, M. Preventive effect of hesperidin against inflammation in CD-1 mouse skin caused by tumor promoter. Anticancer Res. 1999, 19, 3237–3241.
166. Aranganathan, S.; Nalini, N. Efficacy of the potential chemopreventive agent, hesperetin (Citrus flavanone), on 1,2-dimethylhydrazine induced colon carcinogenesis. Food Chem. Toxicol. 2009, 47, 2594–2600.
167. Choi, E.J.; Kim, G.H. Anti-/pro-apoptotic effects of hesperetin against 7,12-dimetylbenz(a)anthraceneinduced alteration in animals. Oncol. Rep. 2011, 25, 545–550.
168. Kamaraj, S.; Ramakrishnan, G.; Anandakumar, P.; Jagan, S.; Devaki, T. Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice. Investig. New Drugs 2009, 27, 214–222.
169. Ye, L.; Chan, F.L.; Chen, S.A.; Leung, L.K. The Citrus flavonone hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice. J. Nutr. Biochem. 2012, 23, 1230–1237.
170. Hung, J.Y.; Hsu, Y.L.; Ko, Y.C.; Tsai, Y.M.; Yang, C.J.; Huang, M.S.; Kuo, P.L. Didymin, a dietary flavonoid glycoside from Citrus fruits, induces FAS-mediated apoptotic pathway in human non-small-cell lung cancer cells in vitro and in vivo. Lung Cancer 2010, 68, 366–374.
171. Saralamma, V.V.G.; Nagappan, A.; Hong, G.E.; Lee, H.J.; Yumnam, S.; Raha, S.; Heo, J.D.; Lee, S.J.; Lee, W.S.; Kim, E.H.; et al. Poncirin induces apoptosis in AGS human gastric cancer cells through extrinsic apoptotic pathway by up-regulation of FAS ligand. Int. J. Mol. Sci. 2015, 16, 22676–22691.
172. Wang, L.S.; Stoner, G.D. Anthocyanins and their role in cancer prevention. Cancer Lett. 2008, 269, 281–290.
173. Schindler, R.; Mentlein, R. Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J. Nutr. 2006, 136, 1477–1482.
174. Freitas, S.; Costa, S.; Azevedo, C.; Carvalho, G.; Freire, S.; Barbosa, P.; Velozo, E.; Schaer, R.; Tardy, M.; Meyer, R.; et al. Flavonoids inhibit angiogenic cytokine production by human glioma cells. Phytother. Res. 2011, 25, 916–921.
175. Liu, L.Z.; Fang, J.; Zhou, Q.; Hu, X.W.; Shi, X.L.; Jiang, B.H. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: Implication of chemoprevention of lung cancer. Mol. Pharmacol. 2005, 68, 635–643.
176. Fang, J.; Zhou, Q.; Liu, L.Z.; Xia, C.; Hu, X.W.; Shi, X.L.; Jiang, B.H. Apigenin inhibits tumor angiogenesis through decreasing HIF-1 alpha and VEGF expression. Carcinogenesis 2007, 28, 858–864.
177. Kim, M.H. Flavonoids inhibit VEGF/BFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J. Cell. Biochem. 2003, 89, 529–538.
178. Lamy, S.; Akla, N.; Ouanouki, A.; Lord-Dufour, S.; Beliveau, R. Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/Stat3 pathway. Exp. Cell Res. 2012, 318, 1586–1596.
179. Lam, I.K.; Alex, D.; Wang, Y.H.; Liu, P.; Liu, A.L.; Du, G.H.; Lee, S.M. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. Mol. Nutr. Food Res. 2012, 56, 945–956.
180. Kunimasa, K.; Ikekita, M.; Sato, M.; Ohta, T.; Yamori, Y.; Ikeda, M.; Kuranuki, S.; Oikawa, T. Nobiletin, a Citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo. Cancer Sci. 2010, 101, 2462–2469.
181. Wang, Y.; Su, M.; Yin, J.; Zhang, H. Effect of nobiletin on K562 cells xenograft in nude mice. Zhongguo Zhong Yao Za Zhi 2009, 34, 1410–1414.
182. Tan, W.F.; Lin, L.P.; Li, M.H.; Zhang, Y.X.; Tong, Y.G.; Xiao, D.; Ding, J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur. J. Pharmacol. 2003, 459, 255–262.
183. Ahn, M.R.; Kunimasa, K.; Kumazawa, S.; Nakayama, T.; Kaji, K.; Uto, Y.; Hori, H.; Nagasawa, H.; Ohta, T. Correlation between antiangiogenic activity and antioxidant activity of various components from propolis. Mol. Nutr. Food Res. 2009, 53, 643–651.
184. Weng, C.J.; Yen, G.C. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastas. Rev. 2012, 31, 323–351.
185. Bracke, M.E.; Boterberg, T.; Depypere, H.T.; Stove, C.; Leclercq, G.; Mareel, M.M. The Citrus methoxyflavone tangeretin affects human cell-cell interactions. Flavonoids Cell Funct. 2002, 505, 135–139.
186. Tan, T.W.; Chou, Y.E.; Yang, W.H.; Hsu, C.J.; Fong, Y.C.; Tang, C.H. Naringin suppress chondrosarcoma migration through inhibition vascular adhesion molecule-1 expression by modulating mir-126. Int. Immunopharmacol. 2014, 22, 107–114.
187. Liao, A.C.H.; Kuo, C.C.; Huang, Y.C.; Yeh, C.W.; Hseu, Y.C.; Liu, J.Y.; Hsu, L.S. Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2. Mol. Med. Rep. 2014, 10, 1531–1536.
188. Martinez Conesa, C.; Vicente Ortega, V.; Yanez Gascon, M.J.; Alcaraz Banos, M.; Canteras Jordana, M.; Benavente-Garcia, O.; Castillo, J. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. J. Agric. Food Chem. 2005, 53, 6791–6797.
189. Lentini, A.; Forni, C.; Provenzano, B.; Beninati, S. Enhancement of transglutaminase activity and polyamine depletion in B16-F10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential. Amino Acids 2007, 32, 95–100.
190. Qin, L.; Jin, L.T.; Lu, L.L.; Lu, X.Y.; Zhang, C.L.; Zhang, F.Y.; Liang, W. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell 2011, 2, 507–516.
191. Miyata, Y.; Sato, T.; Imada, K.; Dobashi, A.; Yano, M.; Ito, A. A Citrus polymethoxyflavonoid, nobiletin, is a novel mek inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells. Biochem. Biophys. Res. Commun. 2008, 366, 168–173.
192. Sato, T.; Koike, L.; Miyata, Y.; Hirata, M.; Mimaki, Y.; Sashida, Y.; Yano, M.; Ito, A. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and-9 in human fibrosarcoma HT-1080 cells. Cancer Res. 2002, 62, 1025–1029.
193. Kawabata, K.; Murakami, A.; Ohigashi, H. Nobiletin, a Citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci. Biotechnol. Biochem. 2005, 69, 307–314.
194. Chien, S.Y.; Hsieh, M.J.; Chen, C.J.; Yang, S.F.; Chen, M.K. Nobiletin inhibits invasion and migration of human nasopharyngeal carcinoma cell lines by involving ERK1/2 and transcriptional inhibition of MMP-2. Expert Opin. Ther. Targets 2015, 19, 307–320.
195. Baek, S.H.; Kim, S.M.; Nam, D.; Lee, J.H.; Ahn, K.S.; Choi, S.H.; Kim, S.H.; Shim, B.S.; Chang, I.M.; Ahn, K.S. Antimetastatic effect of nobiletin through the down-regulation of CXC chemokine receptor type 4 and matrix metallopeptidase-9. Pharm. Biol. 2012, 50, 1210–1218.
196. Minagawa, A.; Otani, Y.; Kubota, T.; Wada, N.; Furukawa, T.; Kumai, K.; Kameyama, K.; Okada, Y.; Fujii, M.; Yano, M.; et al. The Citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn. J. Cancer Res. 2001, 92, 1322–1328.
197. Lee, Y.C.; Cheng, T.H.; Lee, J.S.; Chen, J.H.; Liao, Y.C.; Fong, Y.; Wu, C.H.; Shih, Y.W. Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/AKT and small GTPase signals in human gastric adenocarcinoma AGS cells. Mol. Cell. Biochem. 2011, 347, 103–115.
198. Da, C.; Liu, Y.; Zhan, Y.; Liu, K.; Wang, R. Nobiletin inhibits epithelial-mesenchymal transition of human non-small cell lung cancer cells by antagonizing the TGF-BETA1/SMAD3 signaling pathway. Oncol. Rep. 2016, 35, 2767–2774.
199. Lindenmeyer, F.; Li, H.; Menashi, S.; Soria, C.; Lu, H. Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr. Cancer Int. J. 2001, 39, 139–147.
200. Lee, W.J.; Chen, W.K.; Wang, C.J.; Lin, W.L.; Tseng, T.H. Apigenin inhibits hgf-promoted invasive growth and metastasis involving blocking PI3K/AKT pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol. 2008, 226, 178–191.
201. Franzen, C.A.; Amargo, E.; Todorovic, V.; Desai, B.V.; Huda, S.; Mirzoeva, S.; Chiu, K.; Grzybowski, B.A.; Chew, T.L.; Green, K.J.; et al. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism. Cancer Prev. Res. 2009, 2, 830–841.
202. Hu, X.W.; Meng, D.; Fang, J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis 2008, 29, 2369–2376.
203. Czyz, J.; Madeja, Z.; Irmer, U.; Korohoda, W.; Hulser, D.F. Flavonoid apigenin inhibits motility and invasiveness of carcinoma cells in vitro. Int. J. Cancer 2005, 114, 12–18.
204. Tatsuta, M.; Iishi, H.; Baba, M.; Yano, H.; Murata, K.; Mukai, M.; Akedo, H. Suppression by apigenin of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats. Clin. Exp. Metastas. 2001, 18, 657–662.
205. Noh, H.J.; Sung, E.G.; Kim, J.Y.; Lee, T.J.; Song, I.H. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by apigenin via the inhibition of p38 mitogen-activated protein kinase-dependent matrix metalloproteinase-9 expression. Oncol. Rep. 2010, 24, 277–283.
206. Caltagirone, S.; Rossi, C.; Poggi, A.; Ranelletti, F.O.; Natali, P.G.; Brunetti, M.; Aiello, F.B.; Piantelli, M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 2000, 87, 595–600.
207. Lin, C.W.; Hou, W.C.; Shen, S.C.; Juan, S.H.; Ko, C.H.; Wang, L.M.; Chen, Y.C. Quercetin inhibition of tumor invasion via suppressing PKC DELTA/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 2008, 29, 1807–1815.
208. Phromnoi, K.; Yodkeeree, S.; Anuchapreeda, S.; Limtrakul, P. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol. Sin. 2009, 30, 1169–1176.
209. Vijayababu, M.R.; Arunkumar, A.; Kanagaraj, P.; Venkataraman, P.; Krishnamoorthy, G.; Arunakaran, J. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol. Cell. Biochem. 2006, 287, 109–116.
210. Senthilkumar, K.; Arunkumar, R.; Elumalai, P.; Sharmila, G.; Gunadharini, D.N.; Banudevi, S.; Krishnamoorthy, G.; Benson, C.S.; Arunakaran, J. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem. Funct. 2011, 29, 87–95.
211. Chiu, W.T.; Shen, S.C.; Chow, J.M.; Lin, C.W.; Shia, L.T.; Chen, Y.C. Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation. Neurobiol. Dis. 2010, 37, 118–129.
212. Labbe, D.; Provencal, M.; Lamy, S.; Boivin, D.; Gingras, D.; Beliveau, R. The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factor-induced medulloblastoma cell migration. J. Nutr. 2009, 139, 646–652.
213. Lin, Y.S.; Tsai, P.H.; Kandaswami, C.C.; Cheng, C.H.; Ke, F.C.; Lee, P.P.; Hwang, J.J.; Lee, M.T. Effects of dietary flavonoids, luteolin, and quercetin on the reversal of epithelial-mesenchymal transition in A431 epidermal cancer cells. Cancer Sci. 2011, 102, 1829–1839.
214. Zhang, W.; Zhang, F. Effects of quercetin on proliferation, apoptosis, adhesion and migration, and invasion of HeLa cells. Eur. J. Gynaecol. Oncol. 2009, 30, 60–64.
215. Zhang, X.M.; Huang, S.P.; Xu, Q. Quercetin inhibits the invasion of murine melanoma B16-BL6 cells by decreasing pro-MMP-9 via the PKC pathway. Cancer Chemother. Pharmacol. 2004, 53, 82–88.
216. Devipriya, S.; Ganapathy, V.; Shyamaladevi, C.S. Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin. Chem. Biol. Interact. 2006, 162, 106–113.
217. Hsu, Y.L.; Hsieh, C.J.; Tsai, E.M.; Hung, J.Y.; Chang, W.A.; Hou, M.F.; Kuo, P.L. Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment. Oncol. Lett. 2016, 11, 1035–1042.
218. Liu, R.H. Potential synergy of phytochemicals in cancer prevention: Mechanism of action. J. Nutr. 2004, 134, 3479S–3485S.
219. So, F.V.; Guthrie, N.; Chambers, A.F.; Moussa, M.; Carroll, K.K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr. Cancer Int. J. 1996, 26, 167–181.
220. Guthrie, N.; Carroll, K.K. Inhibition of mammary cancer by Citrus flavonoids. Flavonoids Cell Funct. 1998, 439, 227–236.
221. Miyagi, Y.; Om, A.S.; Chee, K.M.; Bennink, M.R. Inhibition of azoxymethane-induced colon cancer by orange juice. Nutr. Cancer Int. J. 2000, 36, 224–229.
222. Tanaka, T.; Kohno, H.; Murakami, M.; Shimada, R.; Kagami, S.; Sumida, T.; Azuma, Y.; Ogawa, H. Suppression of azoxymethane-induced colon carcinogenesis in male F344 rats by mandarin juices rich in beta-cryptoxanthin and hesperidin. Int. J. Cancer 2000, 88, 146–150.
223. Kohno, H.; Taima, M.; Sumida, T.; Azuma, Y.; Ogawa, H.; Tanaka, T. Inhibitory effect of mandarin juice rich in beta-cryptoxanthin and hesperidin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary tumorigenesis in mice. Cancer Lett. 2001, 174, 141–150.
224. Tanaka, T.; Tanaka, T.; Tanaka, M.; Kuno, T. Cancer chemoprevention by Citrus pulp and juices containing high amounts of beta-cryptoxanthin and hesperidin. J. Biomed. Biotechnol. 2012, 2012, 516981.
225. Kohno, H.; Maeda, M.; Honjo, S.; Murakami, M.; Shimada, R.; Masuda, S.; Sumida, T.; Azuma, Y.; Ogawa, H.; Tanaka, T. Prevention of colonic preneoplastic lesions by the β-cryptoxanthin and hesperidin rich powder prepared from Citrus unshiu marc. Juice in male f344 rats. J. Toxicol. Pathol. 1999, 12, 209–215.
226. Celano, M.; Maggisano, V.; De Rose, R.F.; Bulotta, S.; Maiuolo, J.; Navarra, M.; Russo, D. Flavonoid fraction of Citrus reticulata juice reduces proliferation and migration of anaplastic thyroid carcinoma cells. Nutr. Cancer Int. J. 2015, 67, 1183–1190.
227. Alshatwi, A.A.; Shafi, G.; Hasan, T.N.; Al-Hazzani, A.A.; Alsaif, M.A.; Alfawaz, M.A.; Lei, K.Y.; Munshi, A. Apoptosis-mediated inhibition of human breast cancer cell proliferation by lemon Citrus extract. Asian Pac. J. Cancer Prev. 2011, 12, 1555–1559.
228. Kim, J.; Jayaprakasha, G.K.; Uckoo, R.M.; Patil, B.S. Evaluation of chemopreventive and cytotoxic effect of lemon seed extracts on human breast cancer (MCF-7) cells. Food Chem. Toxicol. 2012, 50, 423–430.
229. Delle Monache, S.; Sanita, P.; Trapasso, E.; Ursino, M.R.; Dugo, P.; Russo, M.; Ferlazzo, N.; Calapai, G.; Angelucci, A.; Navarra, M. Mechanisms underlying the anti-tumoral effects of Citrus bergamia juice. PLoS ONE 2013, 8, e61484.
230. Ferlazzo, N.; Cirmi, S.; Russo, M.; Trapasso, E.; Ursino, M.R.; Lombardo, G.E.; Gangemi, S.; Calapai, G.; Navarra, M. NF-κB mediates the antiproliferative and proapoptotic effects of bergamot juice in HepG2 cells. Life Sci. 2016, 146, 81–91.
231. Navarra, M.; Ursino, M.R.; Ferlazzo, N.; Russo, M.; Schumacher, U.; Valentiner, U. Effect of Citrus bergamia juice on human neuroblastoma cells in vitro and in metastatic xenograft models. Fitoterapia 2014, 95, 83–92.
232. Visalli, G.; Ferlazzo, N.; Cirmi, S.; Campiglia, P.; Gangemi, S.; Di Pietro, A.; Calapai, G.; Navarra, M. Bergamot juice extract inhibits proliferation by inducing apoptosis in human colon cancer cells. Anticancer Agents Med. Chem. 2014, 14, 1402–1413.
233. Balkwill, F.; Mantovani, A. Inflammation and cancer: Back to virchow? Lancet 2001, 357, 539–545.
234. Crawford, S. Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: A new therapeutic approach to disease progression and recurrence. Ther. Adv. Med. Oncol. 2014, 6, 52–68.
235. Ferlazzo, N.; Visalli, G.; Smeriglio, A.; Cirmi, S.; Lombardo, G.E.; Campiglia, P.; di Pietro, A.; Navarra, M. Flavonoid fraction of orange and bergamot juices protect human lung epithelial cells from hydrogen peroxide-induced oxidative stress. Evid. Based Complement. Altern. Med. 2015, 2015, 957031.
236. Ferlazzo, N.; Visalli, G.; Cirmi, S.; Lombardo, G.E.; Lagana, P.; di Pietro, A.; Navarra, M. Natural iron chelators: Protective role in A549 cells of flavonoids-rich extracts of Citrus juices in Fe3+-induced oxidative stress. Environ. Toxicol. Pharmacol. 2016, 43, 248–256.
237. Risitano, R.; Currò, M.; Cirmi, S.; Ferlazzo, N.; Campiglia, P.; Caccamo, D.; Ientile, R.; Navarra, M. Flavonoid fraction of bergamot juice reduces LPS-induced inflammatory response through SIRT1-mediated NF-kB inhibition in THP-1 monocytes. PLoS ONE 2014, 9, e107431.
238. Currò, M.; Risitano, R.; Ferlazzo, N.; Cirmi, S.; Gangemi, C.; Caccamo, D.; Ientile, R.; Navarra, M. Citrus bergamia juice extract attenuates beta-amyloid-induced pro-inflammatory activation of THP-1 cells through MAPK and AP-1 pathways. Sci. Rep. 2016, 6, 20809.
239. Impellizzeri, D.; Bruschetta, G.; di Paola, R.; Ahmad, A.; Campolo, M.; Cuzzocrea, S.; Esposito, E.; Navarra, M. The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease. Clin. Nutr. 2015, 34, 1146–1154.
240. Impellizzeri, D.; Cordaro, M.; Campolo, M.; Gugliandolo, E.; Esposito, E.; Benedetto, F.; Cuzzocrea, S.; Navarra, M. Anti-inflammatory and antioxidant effects of flavonoid-rich fraction of bergamot juice (BJe) in a mouse model of intestinal ischemia/reperfusion injury. FASEB J. 2016, 30 (Suppl. 1), 720–725.
241. Filocamo, A.; Bisignano, C.; Ferlazzo, N.; Cirmi, S.; Mandalari, G.; Navarra, M. In vitro effect of bergamot (Citrus bergamia) juice against cagA-positive and-negative clinical isolates of helicobacter pylori. BMC Complement. Altern. Med. 2015, 15. [CrossRef]
242. Cirmi, S.; Bisignano, C.; Mandalari, G.; Navarra, M. Anti-infective potential of Citrus bergamia risso et poiteau (bergamot) derivatives: A systematic review. Phytother. Res. 2016. [CrossRef]
243. Marino, A.; Paterniti, I.; Cordaro, M.; Morabito, R.; Campolo, M.; Navarra, M.; Esposito, E.; Cuzzocrea, S. Role of natural antioxidants and potential use of bergamot in treating rheumatoid arthritis. PharmaNutrition 2015, 3, 53–59.
244. Mak, N.K.; WongLeung, Y.L.; Chan, S.C.; Wen, J.M.; Leung, K.N.; Fung, M.C. Isolation of anti-leukemia compounds from Citrus reticulata. Life Sci. 1996, 58, 1269–1276.
245. Kim, M.J.; Park, H.J.; Hong, M.S.; Park, H.J.; Kim, M.S.; Leem, K.H.; Kim, J.B.; Kim, Y.J.; Kim, H.K. Citrus reticulata blanco induces apoptosis in human gastric cancer cells SNU-668. Nutr. Cancer 2005, 51, 78–82.
246. Park, K.I.; Park, H.S.; Nagappan, A.; Hong, G.E.; Lee, D.H.; Kang, S.R.; Kim, J.A.; Zhang, J.; Kim, E.H.; Lee, W.S.; et al. Induction of the cell cycle arrest and apoptosis by flavonoids isolated from korean Citrus aurantium L. In non-small-cell lung cancer cells. Food Chem. 2012, 135, 2728–2735.
247. Han, M.H.; Lee, W.S.; Lu, J.N.; Kim, G.; Jung, J.M.; Ryu, C.H.; Kim, G.Y.; Hwang, H.J.; Kwon, T.K.; Choi, Y.H. Citrus aurantium L. exhibits apoptotic effects on U937 human leukemia cells partly through inhibition of AKT. Int. J. Oncol. 2012, 40, 2090–2096.
248. Adina, A.B.; Goenadi, F.A.; Handoko, F.F.; Nawangsari, D.A.; Hermawan, A.; Jenie, R.I.; Meiyanto, E. Combination of ethanolic extract of Citrus aurantifolia peels with doxorubicin modulate cell cycle and increase apoptosis induction on MCF-7 cells. Iran. J. Pharm. Res. 2014, 13, 919–926.
249. Wang, B.; Lin, S.Y.; Shen, Y.Y.; Wu, L.Q.; Chen, Z.Z.; Li, J.; Chen, Z.; Qian, W.B.; Jiang, J.P. Pure total flavonoids from Citrus paradisi Macfadyen act synergistically with arsenic trioxide in inducing apoptosis of kasumi-1 leukemia cells in vitro. J. Zhejiang Univ. Sci. B 2015, 16, 580–585.
250. Celia, C.; Trapasso, E.; Locatelli, M.; Navarra, M.; Ventura, C.A.; Wolfram, J.; Carafa, M.; Morittu, V.M.; Britti, D.; di Marzio, L.; et al. Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells. Colloids Surf. B Biointerfaces 2013, 112, 548–553.
251. Navarra, M.; Ferlazzo, N.; Cirmi, S.; Trapasso, E.; Bramanti, P.; Lombardo, G.E.; Minciullo, P.L.; Calapai, G.; Gangemi, S. Effects of bergamot essential oil and its extractive fractions on SH-SY5Y human neuroblastoma cell growth. J. Pharm. Pharmacol. 2015, 67, 1042–1053.
252. Yuan, J.M.; Wang, X.L.; Xiang, Y.B.; Gao, Y.T.; Ross, R.K.; Yu, M.C. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int. J. Cancer 2000, 85, 358–363.
253. Bosetti, C.; la Vecchia, C.; Talamini, R.; Simonato, L.; Zambon, P.; Negri, E.; Trichopoulos, D.; Lagiou, P.; Bardini, R.; Franceschi, S. Food groups and risk of squamous cell esophageal cancer in northern Italy. Int. J. Cancer 2000, 87, 289–294.
254. Steevens, J.; Schouten, L.J.; Goldbohm, R.A.; van den Brandt, P.A. Vegetables and fruits consumption and risk of esophageal and gastric cancer subtypes in the Netherlands cohort study. Int. J. Cancer 2011, 129, 2681–2693.
255. Franceschi, S.; Favero, A.; Conti, E.; Talamini, R.; Volpe, R.; Negri, E.; Barzan, L.; la Vecchia, C. Food groups, oils and butter, and cancer of the oral cavity and pharynx. Br. J. Cancer 1999, 80, 614–620.
256. Bosetti, C.; la Vecchia, C.; Talamini, R.; Negri, E.; Levi, F.; dal Maso, L.; Franceschi, S. Food groups and laryngeal cancer risk: A case-control study from Italy and Switzerland. Int. J. Cancer 2002, 100, 355–360.
257. Maserejian, N.N.; Giovannucci, E.; Rosner, B.; Zavras, A.; Joshipura, K. Prospective study of fruits and vegetables and risk of oral premalignant lesions in men. Am. J. Epidemiol. 2006, 164, 556–566.
258. Pavia, M.; Pileggi, C.; Nobile, C.G.A.; Angelillo, I.F. Association between fruit and vegetable consumption and oral cancer: A meta-analysis of observational studies. Am. J. Clin. Nutr. 2006, 83, 1126–1134.
259. Pourfarzi, F.; Whelan, A.; Kaldor, J.; Malekzadeh, R. The role of diet and other environmental factors in the causation of gastric cancer in Iran-a population based study. Int. J. Cancer 2009, 125, 1953–1960.
260. Foschi, R.; Pelucchi, C.; dal Maso, L.; Rossi, M.; Levi, F.; Talamini, R.; Bosetti, C.; Negri, E.; Serraino, D.; Giacosa, A.; et al. Citrus fruit and cancer risk in a network of case-control studies. Cancer Causes Control 2010, 21, 237–242.
261. Gonzalez, C.A.; Lujan-Barroso, L.; Bueno-de-Mesquita, H.B.; Jenab, M.; Duell, E.J.; Agudo, A.; Tjonneland, A.; Boutron-Ruault, M.C.; Clavel-Chapelon, F.; Touillaud, M.; et al. Fruit and vegetable intake and the risk of gastric adenocarcinoma: A reanalysis of the european prospective investigation into cancer and nutrition (epic-eurgast) study after a longer follow-up. Int. J. Cancer 2012, 131, 2910–2919.
262. Franceschi, S.; Favero, A.; la Vecchia, C.; Negri, E.; Conti, E.; Montella, M.; Giacosa, A.; Nanni, O.; Decarli, A. Food groups and risk of colorectal cancer in Italy. Int. J. Cancer 1997, 72, 56–61.
263. Levi, F.; Pasche, C.; la Vecchia, C.; Lucchini, F.; Franceschi, S. Food groups and colorectal cancer risk. Br. J. Cancer 1999, 79, 1283–1287.
264. Malin, A.S.; Qi, D.; Shu, X.O.; Gao, Y.T.; Friedmann, J.M.; Jin, F.; Zheng, W. Intake of fruits, vegetables and selected micronutrients in relation to the risk of breast cancer. Int. J. Cancer 2003, 105, 413–418.
265. Ronco, A.L.; de Stefani, E.; Stoll, M. Hormonal and metabolic modulation through nutrition: Towards a primary prevention of breast cancer. Breast 2010, 19, 322–332.
266. Jansen, R.J.; Robinson, D.P.; Stolzenberg-Solomon, R.Z.; Bamlet, W.R.; de Andrade, M.; Oberg, A.L.; Hammer, T.J.; Rabe, K.G.; Anderson, K.E.; Olson, J.E.; et al. Fruit and vegetable consumption is inversely associated with having pancreatic cancer. Cancer Causes Control 2011, 22, 1613–1625.
267. Chan, J.M.; Wang, F.; Holly, E.A. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol. Biomark. Prev. 2005, 14, 2093–2097.
268. Jian, L.; Du, C.J.; Lee, A.H.; Binns, C.W. Do dietary lycopene and other carotenoids protect against prostate cancer? Int. J. Cancer 2005, 113, 1010–1014.
269. Fortes, C.; Mastroeni, S.; Melchi, F.; Pilla, M.A.; Antonelli, G.; Camaioni, D.; Alotto, M.; Pasquini, P. A protective effect of the mediterranean diet for cutaneous melanoma. Int. J. Epidemiol. 2008, 37, 1018–1029.
270. Li, W.Q.; Kuriyama, S.; Li, Q.; Nagai, M.; Hozawa, A.; Nishino, Y.; Tsuji, I. Citrus consumption and cancer incidence: The Ohsaki cohort study. Int. J. Cancer 2010, 127, 1913–1922.
271. Dikshit, R.P.; Boffetta, P.; Bouchardy, C.; Merletti, F.; Crosignani, P.; Cuchi, T.; Ardanaz, E.; Brennan, P. Risk factors for the development of second primary tumors among men after laryngeal and hypopharyngeal carcinoma—A multicentric european study. Cancer 2005, 103, 2326–2333.
272. Bae, J.M.; Lee, E.J.; Guyatt, G. Citrus fruit intake and stomach cancer risk: A quantitative systematic review. Gastric Cancer 2008, 11, 23–32.
273. Bae, J.M.; Lee, E.J.; Guyatt, G. Citrus fruit intake and pancreatic cancer risk: A quantitative systematic review. Pancreas 2009, 38, 168–174.
274. Song, J.K.; Bae, J.M. Citrus fruit intake and breast cancer risk: A quantitative systematic review. J. Breast Cancer 2013, 16, 72–76.
275. Liang, S.; Lv, G.; Chen, W.; Jiang, J.; Wang, J. Citrus fruit intake and bladder cancer risk: A meta-analysis of observational studies. Int. J. Food Sci. Nutr. 2014, 65, 893–898.
276. Xu, C.; Zeng, X.T.; Liu, T.Z.; Zhang, C.; Yang, Z.H.; Li, S.; Chen, X.Y. Fruits and vegetables intake and risk of bladder cancer: A prisma-compliant systematic review and dose-response meta-analysis of prospective cohort studies. Medicine 2015, 94, e759.
277. Yao, B.; Yan, Y.; Ye, X.; Fang, H.; Xu, H.; Liu, Y.; Li, S.; Zhao, Y. Intake of fruit and vegetables and risk of bladder cancer: A dose-response meta-analysis of observational studies. Cancer Causes Control 2014, 25, 1645–1658.
278. Wang, A.; Zhu, C.; Fu, L.; Wan, X.; Yang, X.; Zhang, H.; Miao, R.; He, L.; Sang, X.; Zhao, H. Citrus fruit intake substantially reduces the risk of esophageal cancer: A meta-analysis of epidemiologic studies. Medicine 2015, 94, e1390.
279. Vingeliene, S.; Chan, D.S.; Aune, D.; Vieira, A.R.; Polemiti, E.; Stevens, C.; Abar, L.; Rosenblatt, D.N.; Greenwood, D.C.; Norat, T. An update of the WCRF/AICR systematic literature review on esophageal and gastric cancers and Citrus fruits intake. Cancer Causes Control 2016, 27, 837–851.
280. Vrieling, A.; Verhage, B.A.; van Duijnhoven, F.J.; Jenab, M.; Overvad, K.; Tjonneland, A.; Olsen, A.; Clavel-Chapelon, F.; Boutron-Ruault, M.C.; Kaaks, R.; et al. Fruit and vegetable consumption and pancreatic cancer risk in the european prospective investigation into cancer and nutrition. Int. J. Cancer 2009, 124, 1926–1934.
281. Ferlazzo, N.; Cirmi, S.; Calapai, G.; Ventura-Spagnolo, E.; Gangemi, S.; Navarra, M. Anti-inflammatory activity of Citrus bergamia derivatives: Where do we stand? Molecules 2016, 21, 1273. [CrossRef]
282. Mannucci, C.; Navarra, M.; Calapai, F.; Squeri, R.; Gangemi, S.; Calapai, G. Clinical Pharmacology of Citrus bergamia: A Systematic Review. Phytother. Res. 2016. [CrossRef]
283. Cirmi, S.; Ferlazzo, N.; Lombardo, G.E.; Ventura-Spagnolo, E.; Gangemi, S.; Calapai, G.; Navarra, M. Neurodegenerative diseases: Might Citrus flavonoids play a protective role? Molecules 2016, 21, 1312. [CrossRef]
284. Citraro, R.; Navarra, M.; Leo, A.; Donato Di Paola, E.; Santangelo, E.; Lippiello, P.; Aiello, R.; Russo, E.; De Sarro, G. The anticonvulsant activity of a flavonoid-rich extract from orange juice involves both NMDA and GABA-benzodiazepine receptor complexes. Molecules 2016, 21. [CrossRef]
285. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets 2011, 12, 122–132.